TY - JOUR
T1 - Standards, Options et Recommandations pour le traitement péri-opératoire des patients atteints d'un cancer bronchique non à petites cellules réséquable d'emblée, opérables (mise à jour), rapport abrégé
AU - Besse, Benjamin
AU - Depierre, Alain
AU - Guillo, Sylvie
AU - Guerche, Clotilde Séblain El
AU - Douillard, Jean Yves
AU - Giniès, Annie
AU - Hennequin, Christophe
AU - Le Pêchoux, Cécile
AU - Milleron, Bernard
AU - Moro-Sibilot, Denis
AU - Mouillefarine, Pierre
AU - Quoix, Elisabeth
AU - Régnard, Jean François
AU - Riquet, Marc
AU - Vaylet, Fabien
AU - Zaleman, Gérard
PY - 2007/10/1
Y1 - 2007/10/1
N2 - An update of the SOR-CPG for the perioperative treatment of operable patients with resecable non small cell lung cancer has been initiated by the French National Federation of Cancer Centres (FNCLCC). This work was performed in collaboration with the French intergroup for thoracic oncology (IFCT), the French speaking language society of pneumology (SPLF), specialists from university or general hospitals and private clinics, and with the French National Cancer Institute. It is based on the methodology developed and used in the "Standards, Options and Recommendations" program. This article presents a short version of the updated 2007 recommendations. Methods. The guideline development process is based on literature review and critical appraisal by a multidisciplinary group of experts. The methodological approach combines systematic review with expert judgement. Recommendations take into account the effectiveness and toxicity of the different therapeutic alternatives and the levels of evidence. Following their development and prior to publication, SOR-guidelines are reviewed by independent practitioners in cancer care delivery. Results. Therapeutic standards and options concerning adjuvant or neoadjuvant chemotherapy as well as adjuvant radiotherapy have been defined per stage (IA, IB, II and IIIA). Specific chemotherapy regimens have also been recommended. Conclusions. After critical appraisal, the literature data appeared sufficient to update the recommendations validated in 2000. The literature will be searched and re-examined in 2008 within SOR's systematic monitoring.
AB - An update of the SOR-CPG for the perioperative treatment of operable patients with resecable non small cell lung cancer has been initiated by the French National Federation of Cancer Centres (FNCLCC). This work was performed in collaboration with the French intergroup for thoracic oncology (IFCT), the French speaking language society of pneumology (SPLF), specialists from university or general hospitals and private clinics, and with the French National Cancer Institute. It is based on the methodology developed and used in the "Standards, Options and Recommendations" program. This article presents a short version of the updated 2007 recommendations. Methods. The guideline development process is based on literature review and critical appraisal by a multidisciplinary group of experts. The methodological approach combines systematic review with expert judgement. Recommendations take into account the effectiveness and toxicity of the different therapeutic alternatives and the levels of evidence. Following their development and prior to publication, SOR-guidelines are reviewed by independent practitioners in cancer care delivery. Results. Therapeutic standards and options concerning adjuvant or neoadjuvant chemotherapy as well as adjuvant radiotherapy have been defined per stage (IA, IB, II and IIIA). Specific chemotherapy regimens have also been recommended. Conclusions. After critical appraisal, the literature data appeared sufficient to update the recommendations validated in 2000. The literature will be searched and re-examined in 2008 within SOR's systematic monitoring.
KW - Adjuvant
KW - Carcinoma
KW - Chemotherapy
KW - Neoadjuvant therapy
KW - Non-small-cell lung
KW - Practice guidelines
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=36248941305&partnerID=8YFLogxK
U2 - 10.1684/bdc.2007.0485
DO - 10.1684/bdc.2007.0485
M3 - Article 'review'
AN - SCOPUS:36248941305
SN - 0007-4551
VL - 94
SP - 887
EP - 896
JO - Bulletin du Cancer
JF - Bulletin du Cancer
IS - 10
ER -